التفاصيل البيبلوغرافية
| العنوان: |
Short- and medium-term efficacy of sodium glucose cotransporter 2 (SGLT-2) inhibitors for the treatment of type 1 diabetes: systematic review and meta-analysis |
| المؤلفون: |
Huang, Yuxin, Jiang, Zeju, Wei, Yiping |
| المصدر: |
Endokrynologia Polska; Vol 71, No 4 (2020); 325-333 |
| بيانات النشر: |
Via Medica |
| سنة النشر: |
2020 |
| المجموعة: |
Via Medica Journals |
| مصطلحات موضوعية: |
sodium-glucose co-transporter 2, therapeutic effects, type 1 diabetes, meta-analysis, systematic review |
| الوصف: |
Introduction: Sodium glucose cotransporter 2 (SGLT2) inhibitors are insulin-independent and glucose-dependent anti-hyperglycaemic drugs that have shown potential as an adjuvant therapy to insulin for the treatment of type 1 diabetes mellitus (T1DM). The purpose of this meta-analysis is to systematically collect available data from randomised trials to determine SGLT-2 inhibitor efficacy in terms of glycaemic control, body mass index, and renal protection when compared with placebo. Material and methods: Cochrane Library, MEDLINE, and EMBASE databases were searched for randomised controlled trials and metaanalyses (without language restrictions) conducted from January 2010 to September 2019. Results: Seventeen randomised controlled trials with 7325 participants were included. Sodium glucose cotransporter 2 therapy significantly reduced the level of glycated haemoglobin (HbA1c) (by 0.37%), body weight (by 2.88 kg), and estimated glomerular filtration (eGFR) (by 0.67 mL/min/1.73 m²) when compared with placebo (all outcomes, p < 0.00001). Subgroup analysis by HbA1c levels showed significant differences between six and 12 months of treatment (p < 0.1). The magnitude of the HbA1c lowering effect waned with longer duration of treatment after six months (up to 12 months). Subgroup analysis by body weight showed significant differences between 1 and 3–4 months of treatment (p < 0.1). Weight loss plateaued after 3–4 months of treatment; subsequently, the weight remained relatively stable until 12 months. Subgroup analysis by eGFR showed significant differences between six and 12 months of treatment (p < 0.1). The magnitude of the eGFR lowering effect increased with longer duration of treatment after six months (up to 12 months). Conclusions: Sodium glucose cotransporter 2 inhibitors show significant therapeutic effects when compared with placebo. Although changes in HbA1c, body weight, and eGFR vary during treatment, the therapeutic effects of SGLT-2 inhibitors measured by these three outcomes can last up to ... |
| نوع الوثيقة: |
other/unknown material |
| وصف الملف: |
application/pdf |
| اللغة: |
English |
| العلاقة: |
https://journals.viamedica.pl/endokrynologia_polska/article/downloadSuppFile/67784/203376Test; https://journals.viamedica.pl/endokrynologia_polska/article/view/EP.a2020.0034Test |
| DOI: |
10.5603/EP.a2020.0034 |
| الإتاحة: |
https://doi.org/10.5603/EP.a2020.0034Test
https://journals.viamedica.pl/endokrynologia_polska/article/view/EP.a2020.0034Test |
| حقوق: |
Completion of the online submission form electronically is tantamount to automatically and free-of-charge transferring of the copyright for publishing and distribution of the submitted material (in all known now and developed in the future forms and fields of exploitation) to the copyright holder, i.e. Polish Society of Endocrinology, under condition that those materials are accepted for publication. The authors agree not to publish any data or figures presented in their work anywhere and in any language without the prior written consent. ; Przesyłając manuskrypt wraz z ilustracjami i tabelami, automatycznie i nieodpłatnie przenosi (przenoszą) na Polskie Towarzystwo Endokrynologiczne i "Endokrynologię Polską". Wszelkie prawa autorskie do wydawania oraz rozpowszechniania nadesłanych materiałów we wszystkich znanych formach i na wszystkich znanych polach eksploatacji, bez ograniczeń terytorialnych językowych, pod warunkiem że materiały te zostaną zaakceptowane do publikacji. Publikacja w całości ani w żadna jej część nie może być powielana ani upowszechniana w jakikolwiek mechaniczny lu elektroniczny sposób bez pisemnej zgody Redaktora Naczelnego. |
| رقم الانضمام: |
edsbas.70EB5BB7 |
| قاعدة البيانات: |
BASE |
